These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 30815825)

  • 21. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
    Cañete F; Mañosa M; Casanova MJ; González-Sueyro RC; Barrio J; Bermejo F; Nos P; Iglesias-Flores E; García-Planella E; Pérez-Calle JL; Vicente R; Vera M; Ramos L; Rivero M; De Francisco R; Montserrat A; Benítez O; Navarro P; Taxonera C; Hinojosa E; Márquez-Mosquera L; Navarro-Llavat M; Ramírez-de la Piscina P; Gomollón F; Rodríguez-Alonso L; Núñez-Alonso A; Fernández-Salazar L; Almela P; Ríos León R; De Castro L; Gisbert JP; Ricart E; Cabré E; Domènech E;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1862-1870. PubMed ID: 31006801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
    Patil SA; Rustgi A; Langenberg P; Cross RK
    Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal healing and anti TNFs in IBD.
    van Assche G; Vermeire S; Rutgeerts P
    Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
    Cañete F; Mañosa M; Pérez-Martínez I; Barreiro-de Acosta M; González-Sueyro RC; Nos P; Iglesias-Flores E; Gutiérrez A; Bujanda L; Gordillo J; Ríos León R; Casanova MJ; Villoria A; Rodríguez-Lago I; López Serrano P; García-Herola A; Ramírez-de la Piscina P; Navarro-Llavat M; Taxonera C; Barrio J; Ramos L; Navarro P; Benítez-Leiva O; Calafat M; Domènech E;
    Clin Transl Gastroenterol; 2020 Aug; 11(8):e00218. PubMed ID: 32955190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
    Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
    J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
    Faleck DM; Shmidt E; Huang R; Katta LG; Narula N; Pinotti R; Suarez-Farinas M; Colombel JF
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):238-245.e4. PubMed ID: 32569749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
    World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.